Clinical Trials

Lymphoma, B-Cell

NCT05888493 2026-04-17

LEDA

109 enrolled

Lymphoma, Follicular, Recurrence

NCT06317662 2026-04-16

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

153 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT06717347 2026-04-16

MK-2140-010

1,046 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06124157 2026-04-14

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

222 enrolled

Burkitt Lymphoma

NCT03914625 2026-04-13

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

6,720 enrolled

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT05675410 2026-04-13

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

1,875 enrolled

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT06925737 2026-04-13

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT07221838 2026-04-09

OCTAGON

Phase 4 Recruiting

75 enrolled

Adrenal Insufficiency, Myasthenia Gravis

NCT01679119 2026-04-07

INCA

Phase 2 Completed

129 enrolled 7 charts

Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-04-02

MK-2140-011

594 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07005154 2026-04-02

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

218 enrolled

Prostatic Neoplasms

NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Phase 2 Withdrawn

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

NCT03959085 2026-03-31

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

5,951 enrolled

Phase 2 Active not recruiting

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT05761171 2026-03-31

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

78 enrolled

Phase 1 Active not recruiting

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06421935 2026-03-24

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

141 enrolled

Gynecologic

Ovarian Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

GastrointestinalGynecologic

454 enrolled

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1/2 Recruiting

182 enrolled

BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06091254 2026-03-11

OLYMPIA-1

822 enrolled

Lymphoma, Follicular

NCT06952803 2026-03-10

EvoPAR-PR02

700 enrolled

Prostatic Neoplasms

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

41 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03007147 2026-02-23

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

475 enrolled

Phase 2 Active not recruiting

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03755804 2026-02-23

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

232 enrolled

Phase 2 Active not recruiting

Hodgkin Disease, Neoplasms

NCT03407144 2026-02-19

MK-3475-667

340 enrolled

Hodgkin Disease

NCT00400946 2026-02-13

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

Phase 3 Completed

800 enrolled 22 charts

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Related Side Effects and Adverse Reactions

NCT06091865 2026-02-05

OLYMPIA-3

904 enrolled

Phase 1/2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07387926 2026-02-04

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

50 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06764485 2026-01-28

rechARge

960 enrolled

Phase 3 Not yet recruiting

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT07365995 2026-01-26

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

736 enrolled